Cell Therapy Associated With Endobronchial Valve

Inclusion Criteria: * Diagnosis of severe heterogeneous pulmonary emphysema (at least 10% of total lung parenchyma or 25% of target lobe with density \< -950HU); * Heterogeneity\> 15pp (difference of at least 15 percentage points of lung parenchyma with density greater than -950HU between the treated lobe(s) and the remaining lung on the same side) * Estimates of low or non-existent collateral ventilation (fissure integrity\> 95% measured by VIDA Diagnostics or collateral ventilation measured by negative Chartis® System) * Total lung capacity\> 100% of predicted * Residual volume\> 175% of predicted * FEV1 \<50% of predicted post-bronchodilator * DLCO (diffusing capacity of the lungs for carbon monoxide) \<45% of predicted post-bronchodilator * Body Mass Index (BMI) Greater than 18Kg/m2 and less than 35Kg/m2. * Optimized clinical treatment * Daily physical activities limitation * Possibility of pulmonary rehabilitation * Preserved ventricular function (LVEF\> 40%) * Cessation of smoking ≥ 4 months * Dyspnea MMRC ≥ 2 Exclusion Criteria: * Homogeneous emphysema * Estimated collateral ventilation observed on CT scanned by VIDA vision software (VIDA vision®, VIDA Diagnostics, Iowa-USA) - Fissure integrity on target lobe less than 75%. * Use of continuous systemic corticosteroid therapy\> 20mg QD (quaque die, once a day) of prednisone (or equivalent) * Active lung or extra pulmonary infection * Coronary heart disease and/or severe ventricular dysfunction * Significant renal or hepatic disease * Immunosuppressive disease * Rheumatologic or orthopedic disease limiting physical capacity; * Cognitive inability to understand study procedures; * Impression by clinical research investigators with a lifespan of less than a year1; * Active smoking * Malignant neoplasia with estimated prognosis of survival \<2 years * Psychosocial problems * Pregnancy